NO20043971L - Anti-CCR5 antistoff - Google Patents
Anti-CCR5 antistoffInfo
- Publication number
- NO20043971L NO20043971L NO20043971A NO20043971A NO20043971L NO 20043971 L NO20043971 L NO 20043971L NO 20043971 A NO20043971 A NO 20043971A NO 20043971 A NO20043971 A NO 20043971A NO 20043971 L NO20043971 L NO 20043971L
- Authority
- NO
- Norway
- Prior art keywords
- atcc deposit
- deposit designation
- plasmid designated
- designation pta
- ccr5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8112802A | 2002-02-22 | 2002-02-22 | |
| PCT/US2003/005500 WO2003072766A1 (en) | 2002-02-22 | 2003-02-21 | Anti-ccr5 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043971L true NO20043971L (no) | 2004-11-16 |
Family
ID=27765254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043971A NO20043971L (no) | 2002-02-22 | 2004-09-22 | Anti-CCR5 antistoff |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2058006A1 (pt) |
| JP (1) | JP2006508631A (pt) |
| KR (1) | KR20050004784A (pt) |
| CN (1) | CN1780907B (pt) |
| AT (1) | ATE414142T1 (pt) |
| AU (1) | AU2003217674C1 (pt) |
| CA (1) | CA2476901C (pt) |
| CY (1) | CY1108799T1 (pt) |
| DE (1) | DE60324664D1 (pt) |
| DK (1) | DK1478738T3 (pt) |
| ES (1) | ES2316740T3 (pt) |
| HK (1) | HK1072272A1 (pt) |
| IL (1) | IL163655A0 (pt) |
| MX (1) | MXPA04008153A (pt) |
| NO (1) | NO20043971L (pt) |
| NZ (2) | NZ561465A (pt) |
| PT (1) | PT1478738E (pt) |
| RU (1) | RU2322454C2 (pt) |
| WO (1) | WO2003072766A1 (pt) |
| ZA (1) | ZA200406765B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
| US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
| US7060273B2 (en) | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| TW200720289A (en) * | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| ES2438019T3 (es) * | 2005-07-22 | 2014-01-15 | Cytodyn, Inc. | Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1 |
| MX2009001204A (es) | 2006-08-17 | 2009-02-11 | Hoffmann La Roche | Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico. |
| TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| KR20090052358A (ko) | 2006-09-29 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | Ｃｃｒ5 에 대한 항체 및 이의 용도 |
| CL2008000707A1 (es) | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
| WO2010027501A2 (en) * | 2008-09-05 | 2010-03-11 | Duke University | Anti-lipid antibodies |
| NZ602685A (en) | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US11584797B2 (en) | 2015-06-23 | 2023-02-21 | Cytodyn Inc. | Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| US20180346571A1 (en) * | 2015-11-17 | 2018-12-06 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| IL294113A (en) * | 2020-01-13 | 2022-08-01 | Cytodyn Inc | ccr5-binding factor for the treatment of ccr5-positive metastatic cancer |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| WO2000035409A2 (en) * | 1998-12-16 | 2000-06-22 | Progenics Pharmaceuticals, Inc. | Hiv-i fusion inhibition compounds |
| JP3459386B2 (ja) | 1999-10-15 | 2003-10-20 | Ｓｍｃ株式会社 | 可逆式取付機構を有する流体圧機器 |
-
2003
- 2003-02-21 DK DK03713632T patent/DK1478738T3/da active
- 2003-02-21 EP EP08168669A patent/EP2058006A1/en not_active Withdrawn
- 2003-02-21 PT PT03713632T patent/PT1478738E/pt unknown
- 2003-02-21 CN CN038090600A patent/CN1780907B/zh not_active Expired - Lifetime
- 2003-02-21 AU AU2003217674A patent/AU2003217674C1/en not_active Expired
- 2003-02-21 IL IL16365503A patent/IL163655A0/xx unknown
- 2003-02-21 EP EP03713632A patent/EP1478738B1/en not_active Expired - Lifetime
- 2003-02-21 NZ NZ561465A patent/NZ561465A/en not_active IP Right Cessation
- 2003-02-21 ES ES03713632T patent/ES2316740T3/es not_active Expired - Lifetime
- 2003-02-21 NZ NZ534947A patent/NZ534947A/en not_active IP Right Cessation
- 2003-02-21 RU RU2004128252/13A patent/RU2322454C2/ru not_active IP Right Cessation
- 2003-02-21 KR KR10-2004-7013080A patent/KR20050004784A/ko not_active Application Discontinuation
- 2003-02-21 CA CA2476901A patent/CA2476901C/en not_active Expired - Lifetime
- 2003-02-21 MX MXPA04008153A patent/MXPA04008153A/es active IP Right Grant
- 2003-02-21 WO PCT/US2003/005500 patent/WO2003072766A1/en active Application Filing
- 2003-02-21 DE DE60324664T patent/DE60324664D1/de not_active Expired - Lifetime
- 2003-02-21 AT AT03713632T patent/ATE414142T1/de not_active IP Right Cessation
- 2003-02-21 JP JP2003571454A patent/JP2006508631A/ja active Pending
-
2004
- 2004-08-25 ZA ZA200406765A patent/ZA200406765B/xx unknown
- 2004-09-22 NO NO20043971A patent/NO20043971L/no not_active Application Discontinuation
-
2005
- 2005-05-04 HK HK05103778.7A patent/HK1072272A1/xx not_active IP Right Cessation
-
2009
- 2009-02-12 CY CY20091100160T patent/CY1108799T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1780907B (zh) | 2011-06-15 |
| EP2058006A1 (en) | 2009-05-13 |
| AU2003217674A1 (en) | 2003-09-09 |
| EP1478738A1 (en) | 2004-11-24 |
| WO2003072766A1 (en) | 2003-09-04 |
| CN1780907A (zh) | 2006-05-31 |
| NZ534947A (en) | 2008-03-28 |
| DE60324664D1 (de) | 2008-12-24 |
| PT1478738E (pt) | 2009-02-16 |
| CA2476901C (en) | 2012-10-09 |
| CA2476901A1 (en) | 2003-09-04 |
| JP2006508631A (ja) | 2006-03-16 |
| IL163655A0 (en) | 2005-12-18 |
| RU2004128252A (ru) | 2005-04-10 |
| EP1478738A4 (en) | 2006-05-31 |
| HK1072272A1 (en) | 2005-08-19 |
| MXPA04008153A (es) | 2005-07-05 |
| KR20050004784A (ko) | 2005-01-12 |
| ATE414142T1 (de) | 2008-11-15 |
| EP1478738B1 (en) | 2008-11-12 |
| DK1478738T3 (da) | 2009-03-09 |
| AU2003217674B2 (en) | 2008-10-30 |
| AU2003217674C1 (en) | 2009-03-26 |
| RU2322454C2 (ru) | 2008-04-20 |
| NZ561465A (en) | 2009-04-30 |
| ZA200406765B (en) | 2006-06-28 |
| ES2316740T3 (es) | 2009-04-16 |
| CY1108799T1 (el) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108799T1 (el) | Αντισωμα αντι- ccr5 | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
| LU92710I2 (fr) | Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) | |
| CY1110689T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
| CY1115730T1 (el) | Θεραπευτικοι επιτοποι και χρησεις αυτων | |
| PT778891E (pt) | Anticorpo monoclonal recombinante anti-rhesus d (d7c2) | |
| CO4480111A1 (es) | Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes | |
| DK3572508T1 (da) | Hybrid-antistoffer indeholdende tunge kæder med humane VDJ områder og tungkæde konstante områder fra mus og lette kæder med humane VJ områder og letkæde konstante områder fra mus. | |
| BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
| DE69327229D1 (de) | Multivalente einkettige Antikörper | |
| RS54450B1 (en) | ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| WO2005003171A3 (en) | Modified antibody fragments | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| EP2267034A3 (en) | Gold-binding protein and use thereof | |
| FI960567A (fi) | Monoklonaalinen vasta-aine, joka indusoi apoptoosin | |
| DE69409225T2 (de) | Verbindungen für zielrichtung | |
| DK0388914T3 (da) | Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse | |
| FR2841905B1 (fr) | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications | |
| DK0802924T3 (da) | Lægemiddel til forlænget immunsuppression og eliminering af tumorceller | |
| WO2004050849A8 (en) | Recombinant immunotoxin and use in treating tumors | |
| WO2004029214A8 (en) | Lfa-1 alpha subunit antibodies and methods of use | |
| CY1117275T1 (el) | Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους | |
| TH83706B (th) | แอนติ-5t4 แอนติบอดีที่ถูกฮิวมาไนซ์และคอนจูเกตของแอนติ-5t4 แอนติบอดี/คาลิซีอะไมซิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |